Belluscura, a medical device developer focused on lightweight and portable oxygen enrichment technology, has received approval from the Singapore Health Sciences Authority to distribute the X-PLOR portable oxygen concentrator in Singapore.
Dilok Klaisataporn / shutterstock.com
Tick correct mark to approve document and project concept.
Singapore forms part of the licensed territories covered by the Exclusive License Agreement with InnoMax Medical Device Technologies for the manufacture and distribution of Belluscura’s portable oxygen concentrators, which was signed in August 2023. InnoMax will pay a minimum royalty and a share of profits on the X-PLOR device and accessories.
Approximately 5.9% of adults in Singapore above 40 years of age have chronic obstructive pulmonary disease (COPD).
In the wider region, over 1 million people in Thailand suffer from COPD. The medical oxygen systems market in the Philippines is also expected to register a CAGR of 7.10%, reaching $86 million on account of increasing prevalence of respiratory diseases resulting from air pollution and smoking, leading to higher demand for oxygen therapy systems amongst patients suffering from COPD.
Bob Rauker, chief executive officer, Belluscura, said: “We are very excited to receive this approval, enabling us to launch sales in Singapore, as a first market in the ASEAN region. With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing region.”
